The 988 Suicide & Crisis Lifeline adds nationwide ASL services for Deaf and Hard of Hearing callers
Nov. 2023Important Notices
Pennsylvania implemented the 988 Suicide & Crisis Lifeline last July. Like 911, it is simple to remember. This measure helped make it easier for people to access support during a mental health crisis nationwide.
Support has now expanded to include nationwide American Sign Language (ASL) services for people who are Deaf and Hard of Hearing. Callers who are Deaf, DeafBlind, DeafDisabled, Hard of Hearing, and Late-Deafened can connect directly to a trained 988 Lifeline counselor in ASL using these steps:
Direct dialing to 988 from a videophone will be available soon. In the meantime, ASL callers can call 1-800-273-TALK (8255) from their videophone to reach ASL services.
Support has now expanded to include nationwide American Sign Language (ASL) services for people who are Deaf and Hard of Hearing. Callers who are Deaf, DeafBlind, DeafDisabled, Hard of Hearing, and Late-Deafened can connect directly to a trained 988 Lifeline counselor in ASL using these steps:
- Visit 988lifeline.org.
- Click the “ASL Now” button.
- Follow the prompts.
Direct dialing to 988 from a videophone will be available soon. In the meantime, ASL callers can call 1-800-273-TALK (8255) from their videophone to reach ASL services.
Recent Announcements
Voluntary nationwide recall: Atorvastatin (Alkem – October)
Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.Nov. 2025Pharmacy Updates
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates